Filing summary
Issuer discrepancy: The request identifies Riot Platforms, Inc., but the supplied Form 10-Q is for Venaxis, Inc. This summary reflects the supplied filing, not a Riot Platforms filing.
Business context and reporting period
Venaxis reported for the quarter and nine months ended September 30, 2013. Its principal focus was developing APPY 1, a blood-based acute appendicitis diagnostic test, while pursuing commercialization in Europe after receiving CE marking and seeking FDA clearance. The company also licensed animal-health technology to Ceva Santé Animale.
Financial performance and position
- Revenue: Third-quarter sales were $56,068, versus $6,240 a year earlier; nine-month sales were $56,068, versus $40,756. APPY 1 initial stocking orders generated 2013 sales. License-fee revenue was $21,708 for the quarter and $61,612 for nine months.
- Losses: Third-quarter net loss was $3.072 million, compared with $2.460 million; nine-month net loss was $9.019 million, compared with $6.708 million. Nine-month loss per share was $0.58, versus $1.78, reflecting a substantially higher weighted-average share count following the offering.
- Expenses: Nine-month R&D increased 91% to $5.019 million, primarily due to APPY 1 clinical activity. SG&A rose 4% to $4.105 million. Operating loss was $9.028 million for the nine months.
- Cash flow: Operating activities used $6.930 million in the first nine months, versus $3.602 million in 2012. Financing provided $12.181 million, including $12.970 million in net stock-offering proceeds. Investing used $11.873 million, largely reflecting purchases of short-term investments. Cash at period-end was $4.355 million.
- Liquidity and debt: Cash, cash equivalents and short-term investments totaled approximately $17.288 million; working capital was $15.446 million. Total notes and other obligations were $2.609 million. The commercial-bank mortgage was refinanced in May at a fixed 3.95% rate, with a five-year balloon maturity; the SBA portion carried a 5.86% rate.
- Equity and dilution: The May 2013 offering of 11.5 million shares raised approximately $14.4 million gross and $12.970 million net. It also included warrants for 4.025 million shares at $1.36 per share. Shares outstanding were 21,454,380 at November 5, 2013.
Changes versus the prior comparable period
Nine-month losses and operating cash use increased, with clinical-trial-driven R&D the principal expense driver. APPY 1 sales began, while sales remained small. The company’s liquidity increased following the May equity offering, and mortgage refinancing reduced interest expense. Nine-month interest expense was $107,000, down from $191,000.
Outlook, risks and contingencies
- Management expected near-term operating losses to continue, potentially significantly, and said available working capital should fund estimated needs through the remainder of 2013 and into 2014. This was management’s estimate, not a guarantee.
- Priorities included continuing APPY 1 FDA clinical-trial enrollment, European commercialization, partnership or licensing efforts, and cost control. The filing estimated remaining-2013 capital expenditures of $50,000–$100,000.
- Failure to obtain FDA clearance or generate sufficient APPY 1 revenue could require reliance on other opportunities and could result in impairment of related patent costs. Management warned that insufficient future capital could force reduced R&D or cessation of operations.
- A securities class-action case related to the earlier appendicitis test remained on appeal; the Tenth Circuit had taken the appeal under submission. The company said it believed the claims were without merit.
- The filing reported no material risk-factor changes from the prior quarter. Investment-market exposure was described as limited, though the company monitored investment quality, asset recoverability and liquidity.
Important facts for investors to verify
- Confirm issuer identity: the supplied filing is Venaxis, Inc., not Riot Platforms, Inc.
- Check APPY 1 clinical-trial progress, FDA-clearance prospects and European sales traction.
- Assess cash burn against management’s stated runway and the possibility of further financing or cost reductions.
- Review potential dilution from outstanding options and warrants, including the 4.025 million offering warrants.
- Monitor the appeal in the Wolfe securities case and any material developments.